Limiting the definition of UMN to focus only on life-threatening or severely debilitating diseases risks deprioritising conditions that fit neither of these criteria yet have important negative consequences on patients, carers and society. Under the Commission’s proposal, only 18% of the 111 non-orphan medicines authorised between 2019 and 2022 are very likely to fulfil the proposed UMN criteria, having a heavy impact on research in certain disease areas such as Cardiovascular disease (CVD), diabetes, migraine, HIV, oncology. Read more
